Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12397926 | 0.91 | PPM1D (0.31) | PPM1D | |
| SCHEMBL17340160 | 0.84 | — | — | |
| SCHEMBL12464760 | 0.84 | — | — | |
| SCHEMBL16357118 | 0.84 | — | — | |
| SCHEMBL16317427 | 0.83 | — | — | |
| SCHEMBL14376845 | 0.80 | — | — | |
| SCHEMBL6428158 | 0.78 | PPM1D (0.34) | PPM1D | |
| SCHEMBL2687928 | 0.78 | STAT3 (0.32) | — | |
| SCHEMBL4357092 | 0.78 | — | — | |
| SCHEMBL14107833 | 0.77 | STAT3 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016435-A1 | HYBRID MOLECULES HAVING MIXED VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITORY PROPERTIES | MCGILL UNIVERSITY (CA) | 2010-01-21 | — | — | US | disclosed |
| EP-1094060-B1 | New process for the preparation of retiferol derivatives | BASILEA PHARMACEUTICA AG (CH) | 2004-04-28 | — | — | EP | disclosed |
| US-6437142-B1 | 10,10,10-TRIFLUORO-5,5-DIMETHYL-9-TRIETHYLSILANYLOXY-9-TRIFLUO ROMETHYL-DEC-7-ENAL REACTED WITH TRIETHYL PHOSPHONOACETATE OR ETHYL (TRIMETHYLSILYL) ACETATE AND THEN COUPLING WITH 2-MERCAPTO-BENZOTHIAZOLE | BASILEA PHARMACEUTICA AG (CH) | 2002-08-20 | — | — | US | disclosed |
| US-6403346-B1 | FOR TREATMENT/PREVENTION OF HYPERPROLIFERATIVE SKIN DISEASES (PSORIASIS) AND REVERSING CONDITIONS ASSOCIATED WITH PHOTODAMAGE | BASILEA PHARMACEUTICA AG (CH) | 2002-06-11 | — | — | US | disclosed |
| US-20020028975-A1 | Process for preparing retiferol derivatives | HILPERT HANS (CH) | 2002-03-07 | — | — | US | disclosed |
| US-6310262-B1 | COUPLING CYCLOHEXANONE DERIVATIVE WITH BENZOTHIAZOLE DERIVATIVE TO FORM RETIFEROL DERIVATIVE | BASILEA PHARMACEUTICA AG (CH) | 2001-10-30 | — | — | US | disclosed |
| EP-1094060-A2 | New process for the preparation of retiferol derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-25 | — | — | EP | disclosed |
| US-5581006-A | Synthesis of 19-nor vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1996-12-03 | — | — | US | disclosed |
| US-5563286-A | Synthesis of 19-nor vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0516411-B1 | Intermediates for the synthesis of 19-nor vitamin D compounds | WISCONSIN ALUMNI RES FOUND (US) | 1996-02-21 | — | — | EP | disclosed |
| US-5486636-A | Synthesis of 19-nor vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1996-01-23 | — | — | US | disclosed |
| US-5391755-A | Synthesis of 19-NOR vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1995-02-21 | — | — | US | disclosed |
| US-5281731-A | Synthesis of 19-nor vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1994-01-25 | — | — | US | disclosed |
| EP-0516411-A1 | Intermediates for the synthesis of 19-nor vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1992-12-02 | — | — | EP | disclosed |
| US-5086191-A | Intermediates for the synthesis of 19-nor vitamin D compounds | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1992-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016435-A1 | HYBRID MOLECULES HAVING MIXED VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITORY PROPERTIES | VDR, HDAC3, HDAC4 | PPM1D 4081/4885 |
| US-20020028975-A1 | Process for preparing retiferol derivatives | RBP1, RBP4, NR1H2 | PPM1D 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.